Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9466960 | 0.85 | MTNR1B (0.50) | HTR6MTNR1BMTNR1AFFAR1PRMT5 | |
| SCHEMBL29538416 | 0.83 | MTNR1B (0.48) | HTR6MTNR1BMTNR1AFFAR1PRMT5 | |
| SCHEMBL7703389 | 0.80 | MTNR1A (0.56) | MTNR1BMTNR1AIDO1TDO2ALPI | |
| SCHEMBL7847075 | 0.77 | FFAR1 (0.62) | HTR6MTNR1BMTNR1AFFAR1PRMT5 | |
| SCHEMBL29462285 | 0.77 | HTR6 (0.53) | HTR6MTNR1BMTNR1AIDO1 | |
| SCHEMBL21194619 | 0.77 | HTR6 (0.53) | HTR6MTNR1BMTNR1AIDO1 | |
| SCHEMBL7845908 | 0.77 | FFAR1 (0.62) | HTR6MTNR1BMTNR1AFFAR1PRMT5 | |
| SCHEMBL1470461 | 0.77 | FFAR1 (0.62) | HTR6MTNR1BMTNR1AFFAR1PRMT5 | |
| Aspartic Acid SCHEMBL17727762 | 0.77 | FFAR1 (0.41) | MTNR1BMTNR1AFFAR1TRPM8 | |
| Aspartic Acid SCHEMBL12497588 | 0.77 | FFAR1 (0.41) | MTNR1BMTNR1AFFAR1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888330-B2 | Phosphoramidate derivatives of FAU | WAYNE STATE UNIVERSITY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20080292553-A1 | Phosphoramidate Derivatives of Fau | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-11-27 | — | — | US | disclosed |
| WO-2008073450-A2 | BENZAMIDE COMPOUNDS | GEORGETOWN UNIVERSITY (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007056596-A2 | PHOSPHORAMIDATE DERIVATIVES OF FAU | WAYNE STATE UNIVERSITY (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20060194814-A1 | Benzamide compounds | GEORGETOWN UNIVERSITY | 2006-08-31 | — | — | US | disclosed |
| US-20060194815-A1 | Methods and compositions for modulating serum cortisol levels | GEORGETOWN UNIVERSITY | 2006-08-31 | — | — | US | disclosed |
| WO-2005112922-A9 | BENZAMIDE COMPOUNDS | SAMARITAN PHARMACEUTICALS (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1631289-A2 | ANTI-HIV BENZAMIDE COMPOUNDS | Samaritan Pharmaceuticals, Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1628660-A2 | METHODS AND COMPOSITIONS FOR MODULATING SERUM CORTISOL LEVELS | Samaritan Pharmaceuticals, Inc. (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2005112922-A2 | BENZAMIDE COMPOUNDS | SAMARITAN PHARMACEUTICALS (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005000205-A2 | METHODS AND COMPOSITIONS FOR MODULATING SERUM CORTISOL LEVELS | SAMARITAN PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004108076-A2 | ANTI-HIV BENZAMIDE COMPOUNDS | SAMARITAN PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194815-A1 | Methods and compositions for modulating serum cortisol levels | CRH, SERPINA6, BCHE | HTR6 202/4885MTNR1B 3151/4885MTNR1A 2203/4885 |
| US-20080292553-A1 | Phosphoramidate Derivatives of Fau | DUT, FAU, DPYD | HTR6 2871/4885MTNR1B 3711/4885MTNR1A 3758/4885 |
| US-20060194814-A1 | Benzamide compounds | PIGS, BCAT2, GBA1 | HTR6 3155/4885MTNR1B 3553/4885MTNR1A 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.